XORTX Therapeutics Inc (XRTX : TSX-V)
Common Stock
$2.93
CAD
-0.10 (-3.30%)
Last updated: 2026-06-23
XRTX
XORTX Therapeutics Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-3.30%
1 Month
-7.28%
YTD
-26.75%
Key Statistics
Market Cap
$5.17M
52W High
$9.85
52W Low
$2.42
P/E Ratio
-
50 Day MA
$3.27
200 Day MA
$3.85
Beta
0.15
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/23/2026 | $2.93 | $2.93 | $2.93 | $2.93 | $2.93 | 301 |
| 6/17/2026 | $3.05 | $3.05 | $3.03 | $3.03 | $3.03 | 1,806 |
| 6/16/2026 | $3.00 | $3.00 | $3.00 | $3.00 | $3.00 | 308 |
| 6/15/2026 | $3.00 | $3.00 | $2.93 | $3.00 | $3.00 | 2,825 |
| 6/10/2026 | $3.20 | $3.20 | $3.20 | $3.20 | $3.20 | 1,100 |
| 6/5/2026 | $2.90 | $2.90 | $2.90 | $2.90 | $2.90 | 100 |
| 6/4/2026 | $2.82 | $2.82 | $2.82 | $2.82 | $2.82 | 200 |
| 6/3/2026 | $3.02 | $3.02 | $3.02 | $3.02 | $3.02 | 100 |
| 5/29/2026 | $3.22 | $3.22 | $3.16 | $3.16 | $3.16 | 612 |
| 5/28/2026 | $3.16 | $3.16 | $3.16 | $3.16 | $3.16 | 300 |
Analyst Price Targets
Based on analyst covering XRTX
Wall Street analysts forecast XRTX stock price to rise 2664.5% over the next 12 months.
Consensus
No RatingAvg. Target
C$81.00
+2664.5% Upside
Current Price
C$2.93
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on XRTX's historical volatility
30-Day Vol
145.1%
Annualized
90-Day Vol
128.3%
Annualized
Trend (90d)
+4.3%
Annualized drift
90d Mean
C$2.98
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.95 | C$1.79 โ C$4.86 |
| 60 trading days | C$2.96 | C$1.46 โ C$6.01 |
| 90 trading days | C$2.98 | C$1.25 โ C$7.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.42M
- Profit Margin
- 0.00%
- ROE (TTM)
- -137.44%
- EPS (Diluted)
- -3.49
- Book Value
- 1.31
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
๐ Recent Splits
1-for-5
Apr 6, 2026
1-for-9
Nov 14, 2023
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About XRTX
Articles Featuring XRTX.V
Latest articles and analysis covering XRTX.V
